Quick Answer
Aura Biosciences, Inc. reported Diluted EPS of $1.76 per share (loss) for fiscal year 2025.
Aura Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.76 | -0.6% |
| 2024 | -$1.75 | +9.3% |
| 2023 | -$1.93 | +1.5% |
| 2022 | -$1.96 | +78.1% |
| 2021 | -$8.95 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | +4.8% | +14.9% |
| June 30, 2025 | -$0.47 | -14.6% | +14.5% |
| March 31, 2025 | -$0.55 | -37.5% | -31.0% |
| September 30, 2024 | -$0.42 | +12.5% | -2.4% |
| June 30, 2024 | -$0.41 | +14.6% | -2.5% |
| March 31, 2024 | -$0.40 | +13.0% | +16.7% |
| September 30, 2023 | -$0.48 | +11.1% | +0.0% |
| June 30, 2023 | -$0.48 | -4.3% | -4.3% |
- Aura Biosciences, Inc. showed a decrease of -0.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Aura Biosciences, Inc.’s diluted eps has grown by 80.3% (from $8.95 per share (loss) to $1.76 per share (loss)).
- The most recent figure is from Aura Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: